BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30998183)

  • 1. [Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review].
    Xu B; Xiao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):633-636. PubMed ID: 30998183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Immunotherapy for Acute Myeloid Leukemia.
    Tabata R; Chi S; Yuda J; Minami Y
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D; Zhang X; Zhang X; Xu Y
    Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
    Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
    J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reaserch Advances in Immunotherapy for Acute Myeloid Leukemia--Review].
    Chen ZH; Li YY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2089-2092. PubMed ID: 33283747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults].
    Moritake H
    Rinsho Ketsueki; 2020; 61(6):665-672. PubMed ID: 32624541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
    Spillane DR; Assouline S
    Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Acute Myeloid Leukemia.
    Lichtenegger FS; Krupka C; Köhnke T; Subklewe M
    Semin Hematol; 2015 Jul; 52(3):207-14. PubMed ID: 26111468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in immunotherapy for acute myeloid leukemia.
    Przespolewski A; Szeles A; Wang ES
    Future Oncol; 2018 Apr; 14(10):963-978. PubMed ID: 29542352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
    Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of T Cell Immunotherapy in Acute Myeloid Leukemia.
    Hao F; Sholy C; Wang C; Cao M; Kang X
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches for the immunotherapy of acute myeloid leukemia.
    Geiger TL; Rubnitz JE
    Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
    Mahalleh M; Shabani M; Rayzan E; Rezaei N
    Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.